Groundbreaking smoking cessation study highlights safety of varenicline, bupropion

The largest‐ever trial of pharmacotherapy for smoking cessation, requested of two drug manufacturers by the Food and Drug Administration (FDA), has found no significant increase in neuropsychiatric adverse events from varenicline or bupropion compared with nicotine replacement therapy or placebo. The findings likely will intensify the discussion of whether regulators in the United States and other countries should revisit boxed warnings on the two smoking cessation treatments. Study results were published online April 22 in The Lancet.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: Adverse Events Source Type: research